<DOC>
	<DOC>NCT00371774</DOC>
	<brief_summary>Purpose: To develop a real time national clinical database to support and share best practices, 1. To generate hypotheses for future clinical research 2. To understand how AMEVIVE is used in routine clinical practice/real world setting. Each patient visit will include the following observational endpoints: 1. AMEVIVE dosing 2. Number of courses 3. Concomitant treatment 4. Response to treatment (patient and physician global assessments) 5. Status of other psoriasis-related medical conditions 6. Time to re-treatment.</brief_summary>
	<brief_title>Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Amevive is clinically indicated for the patient Amevive is contraindicated for the patient</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Amevive®</keyword>
	<keyword>alefacept</keyword>
</DOC>